Reduced dose of subcutaneous cladribine induces identical response rates but decreased toxicity in pretreated chronic lymphocytic leukaemia
- 1 July 1998
- journal article
- clinical trial
- Published by Elsevier in Annals of Oncology
- Vol. 9 (7) , 721-726
- https://doi.org/10.1023/a:1008273131598
Abstract
No abstract availableKeywords
This publication has 15 references indexed in Scilit:
- 2-Chlorodeoxyadenosine (2-CDA) therapy in previously untreated patients with follicular stage III–IV non-Hodgkin's lymphomaAnnals of Oncology, 1996
- 2-Chlorodeoxyadenosine treatment in non-Hodgkin's Lymphoma and B-cell chronic lymphocytic leukemia resistant to conventional chemotherapy: results of a multicentric experienceAnnals of Hematology, 1996
- Fludarabine in chronic leukaemiaThe Lancet, 1996
- Long-term survival following cladribine (2-chlorodeoxyadenosine) therapy in previously treated patients with chronic lymphocytic leukemiaAnnals of Oncology, 1996
- 2-Chlorodeoxyadenosine (2-CdA) in 2-Hour Versus 24-Hour Intravenous Infusion in the Treatment of Patients with Hairy Cell LeukemiaLeukemia & Lymphoma, 1996
- Cladribine in the treatment of relapsed or refractory chronic lymphocytic leukemia.Journal of Clinical Oncology, 1995
- High incidence of infections after 2-chlorodeoxyadenosine (2-CDA) therapy in patients with malignant lymphomas and chronic and acute leukaemiasAnnals of Oncology, 1994
- 2-Chlorodeoxyadenosine Treatment of Refractory Chronic Lymphocytic LeukemiaLeukemia & Lymphoma, 1991
- 2-Chlorodeoxyadenosine: an effective new agent for the treatment of chronic lymphocytic leukemiaBlood, 1988
- Synthesis of 2'-deoxytubercidin, 2'-deoxyadenosine, and related 2'-deoxynucleosides via a novel direct stereospecific sodium salt glycosylation procedureJournal of the American Chemical Society, 1984